Crossmark

The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy

Crossref DOI link: https://doi.org/10.1186/s12876-022-02180-6

Published Online: 2022-03-04

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Qi

Qiao, Wenying

Liu, Biyu

Li, Jianjun

Yuan, Chunwang

Long, Jiang

Hu, Caixia

Zang, Chaoran

Zheng, Jiasheng

Zhang, Yonghong
Funding

Funding for this research was provided by:

Natural Science Foundation of Beijing Municipality (7191004)

Alpha Foundation for the Improvement of Mine Safety and Health (CFH2020-1-2182)
License Information

Text and Data Mining valid from 2022-03-04

Version of Record valid from 2022-03-04
More Information

Article History

Received: 27 December 2021

Accepted: 22 February 2022

First Online: 4 March 2022

Declarations

:

: As a minimum risk study that was in accordance with the Helsinki protocol, the requirement for patients’ informed consent was waived, and it was approved by the ethics committee of Beijing You 'an Hospital (No.LL-2019–004-K). The consent obtained from study participants was written, and all methods were carried out in accordance with relevant guidelines and regulations.

: All authors contributed to the article and approved the submitted version.

: Authors declare no Conflicts of Interest for this article.

Document is current

Any future updates will be listed below